Am J Clin Pathol 2001, 115:44–58.selleck products PubMedCrossRef 19. Krecicki T, Zalesska-Krecicka M, Jelen M, Szkudlarek T, Horobiowska M: Expression of type IV collagen and matrix metalloproteinase-2 (type IV collagenase) in relation to nodal status in laryngeal cancer. Clin Otolaryngol Allied Sci 2001, 26:469–472.PubMedCrossRef 20. Santos-Garcia A, Abad-Hernandez

MM, Fonseca-Sanchez E, Julian-Gonzalez R, Galindo-Villardon P, Cruz-Hernandez JJ, Bullon-Sopelana A: E-cadherin, laminin and collagen IV expression in the evolution from dysplasia to oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 2006, 11:E100-E105.PubMed 21. Bar JK, Grelewski P, Popiela A, Noga L, Rabczynski J: Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumours: correlation with Ki-67 and p53 immunoreactivity. Doramapimod Gynecol Oncol 2004, 95:23–31.PubMedCrossRef 22. Ingber DE: Can cancer be reversed by engineering the tumour microenvironment? Semin Cancer Biol 2008, 18:356–364.PubMedCrossRef 23. Albini A, Sporn MB: The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007, 7:139–147.PubMedCrossRef 24. Silzle T, Randolph

GJ, Kreutz M, Kunz-Schughart LA: The fibroblast: sentinel cell and local immune modulator in tumour tissue. Int J Cancer 2004, 108:173–180.PubMedCrossRef 25. Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 2006, 6:392–401.PubMedCrossRef 26. Shimoda M, Mellody KT, Orimo TH-302 order A: Carcinoma-associated fibroblasts are a rate-limiting determinant

for tumour progression. Semin Cell Dev Biol 2010, 21:19–25.PubMedCrossRef 27. Qian BZ, Pollard JW: Macrophage diversity enhances tumour progression and metastasis. Cell 2010, 141:39–51.PubMedCrossRef 28. Mantovani A: La mala educacion of tumour-associated 4��8C macrophages: Diverse pathways and new players. Cancer Cell 2010, 17:111–112.PubMedCrossRef 29. Sobral LM, Bufalino A, Lopes MA, Graner E, Salo T, Coletta RD: Myofibroblasts in the stroma of oral cancer promote tumourigenesis via secretion of activin A. Oral Oncol 2011, 47:840–846.PubMedCrossRef 30. Kamat AA, Fletcher M, Gruman LM, Mueller P, Lopez A, Landen CN Jr, Han L, Gershenson DM, Sood AK: The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 2006, 12:1707–1714.PubMedCrossRef 31. Ranogajec I, Jakic-Razumovic J, Puzovic V, Gabrilovac J: Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients. Med Oncol 2011, 29:561–569.PubMedCrossRef 32. Zhou CX, Gao Y, Johnson NW, Gao J: Immunoexpression of matrix metalloproteinase-2 and matrix metalloproteinase-9 in the metastasis of squamous cell carcinoma of the human tongue. Aust Dent J 2010, 55:385–389.PubMedCrossRef 33.